Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

Karl D. Lewis, James Larkin, Antoni Ribas, Keith T. Flaherty, Grant A. McArthur, Paolo A. Ascierto, Brigitte Dréno, Yibing Yan, Matthew Wongchenko, Edward McKenna, Qian Zhu, Yong Mun, Axel Hauschild

Research output: Contribution to journalArticle

Abstract

Background: This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib. Methods: The data were pooled from BRIM-2, BRIM-3, BRIM-7 and coBRIM. Association of depth of response with survival was estimated by Cox proportional hazards regression, adjusted for clinically relevant covariates. Depth of response was analysed in previously identified prognostic subgroups based on disease characteristics and gene signatures. Results: Greater tumour reduction and longer time to maximal response were significantly associated with longer progression-free survival (PFS) and overall survival (OS) when evaluated as continuous variables. Patients with the deepest responses had long-lasting survival outcomes (median PFS: 14 months; OS: 32 months with vemurafenib; not estimable with cobimetinib plus vemurafenib). Cobimetinib plus vemurafenib improved depth of response versus vemurafenib monotherapy regardless of other prognostic factors, including gene signatures. Conclusions: Greater depth of response was associated with improved survival, supporting its utility as a measure of treatment efficacy in melanoma and further evaluation of its incorporation into existing prognostic models. Cobimetinib plus vemurafenib improved outcomes across quartiles of response regardless of prognostic factors or gene signatures and provided durable survival benefits in patients with deep responses.

Original languageEnglish
JournalBritish Journal of Cancer
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Survival
Disease-Free Survival
Melanoma
Genes
GDC-0973
PLX4032
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib : pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. / Lewis, Karl D.; Larkin, James; Ribas, Antoni; Flaherty, Keith T.; McArthur, Grant A.; Ascierto, Paolo A.; Dréno, Brigitte; Yan, Yibing; Wongchenko, Matthew; McKenna, Edward; Zhu, Qian; Mun, Yong; Hauschild, Axel.

In: British Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Lewis, Karl D. ; Larkin, James ; Ribas, Antoni ; Flaherty, Keith T. ; McArthur, Grant A. ; Ascierto, Paolo A. ; Dréno, Brigitte ; Yan, Yibing ; Wongchenko, Matthew ; McKenna, Edward ; Zhu, Qian ; Mun, Yong ; Hauschild, Axel. / Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib : pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. In: British Journal of Cancer. 2019.
@article{3b51377a02194f8d89b1e6fca6204ef1,
title = "Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM",
abstract = "Background: This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib. Methods: The data were pooled from BRIM-2, BRIM-3, BRIM-7 and coBRIM. Association of depth of response with survival was estimated by Cox proportional hazards regression, adjusted for clinically relevant covariates. Depth of response was analysed in previously identified prognostic subgroups based on disease characteristics and gene signatures. Results: Greater tumour reduction and longer time to maximal response were significantly associated with longer progression-free survival (PFS) and overall survival (OS) when evaluated as continuous variables. Patients with the deepest responses had long-lasting survival outcomes (median PFS: 14 months; OS: 32 months with vemurafenib; not estimable with cobimetinib plus vemurafenib). Cobimetinib plus vemurafenib improved depth of response versus vemurafenib monotherapy regardless of other prognostic factors, including gene signatures. Conclusions: Greater depth of response was associated with improved survival, supporting its utility as a measure of treatment efficacy in melanoma and further evaluation of its incorporation into existing prognostic models. Cobimetinib plus vemurafenib improved outcomes across quartiles of response regardless of prognostic factors or gene signatures and provided durable survival benefits in patients with deep responses.",
author = "Lewis, {Karl D.} and James Larkin and Antoni Ribas and Flaherty, {Keith T.} and McArthur, {Grant A.} and Ascierto, {Paolo A.} and Brigitte Dr{\'e}no and Yibing Yan and Matthew Wongchenko and Edward McKenna and Qian Zhu and Yong Mun and Axel Hauschild",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41416-019-0546-y",
language = "English",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib

T2 - pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

AU - Lewis, Karl D.

AU - Larkin, James

AU - Ribas, Antoni

AU - Flaherty, Keith T.

AU - McArthur, Grant A.

AU - Ascierto, Paolo A.

AU - Dréno, Brigitte

AU - Yan, Yibing

AU - Wongchenko, Matthew

AU - McKenna, Edward

AU - Zhu, Qian

AU - Mun, Yong

AU - Hauschild, Axel

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib. Methods: The data were pooled from BRIM-2, BRIM-3, BRIM-7 and coBRIM. Association of depth of response with survival was estimated by Cox proportional hazards regression, adjusted for clinically relevant covariates. Depth of response was analysed in previously identified prognostic subgroups based on disease characteristics and gene signatures. Results: Greater tumour reduction and longer time to maximal response were significantly associated with longer progression-free survival (PFS) and overall survival (OS) when evaluated as continuous variables. Patients with the deepest responses had long-lasting survival outcomes (median PFS: 14 months; OS: 32 months with vemurafenib; not estimable with cobimetinib plus vemurafenib). Cobimetinib plus vemurafenib improved depth of response versus vemurafenib monotherapy regardless of other prognostic factors, including gene signatures. Conclusions: Greater depth of response was associated with improved survival, supporting its utility as a measure of treatment efficacy in melanoma and further evaluation of its incorporation into existing prognostic models. Cobimetinib plus vemurafenib improved outcomes across quartiles of response regardless of prognostic factors or gene signatures and provided durable survival benefits in patients with deep responses.

AB - Background: This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib. Methods: The data were pooled from BRIM-2, BRIM-3, BRIM-7 and coBRIM. Association of depth of response with survival was estimated by Cox proportional hazards regression, adjusted for clinically relevant covariates. Depth of response was analysed in previously identified prognostic subgroups based on disease characteristics and gene signatures. Results: Greater tumour reduction and longer time to maximal response were significantly associated with longer progression-free survival (PFS) and overall survival (OS) when evaluated as continuous variables. Patients with the deepest responses had long-lasting survival outcomes (median PFS: 14 months; OS: 32 months with vemurafenib; not estimable with cobimetinib plus vemurafenib). Cobimetinib plus vemurafenib improved depth of response versus vemurafenib monotherapy regardless of other prognostic factors, including gene signatures. Conclusions: Greater depth of response was associated with improved survival, supporting its utility as a measure of treatment efficacy in melanoma and further evaluation of its incorporation into existing prognostic models. Cobimetinib plus vemurafenib improved outcomes across quartiles of response regardless of prognostic factors or gene signatures and provided durable survival benefits in patients with deep responses.

UR - http://www.scopus.com/inward/record.url?scp=85070803985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070803985&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0546-y

DO - 10.1038/s41416-019-0546-y

M3 - Article

AN - SCOPUS:85070803985

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -